Clicky

Aligos Therapeutics, Inc.(ALGS)

Description: Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.


Keywords: Medicine Clinical Medicine Alcohol Drug Development Hepatitis Hepatitis B Liver Disease Viruses Coronavirus Steatohepatitis Non Alcoholic Fatty Liver Disease Viral Disease Chronic Hepatitis B Viral Infection Viral Infections Chronic Hepatitis Antiviral Therapies Viral Hepatitis

Home Page: www.aligos.com

ALGS Technical Analysis

One Corporate Drive
South San Francisco, CA 94080
United States
Phone: 800 466 6059


Officers

Name Title
Dr. Lawrence M. Blatt MBA, Ph.D. CEO & Chairman
Dr. Leonid Beigelman Ph.D. Pres & Director
Dr. Julian A. Symons DPHIL Exec. VP & Chief Scientific Officer
Ms. Lesley Ann Calhoun CPA Exec. VP & CFO
Ms. Lucinda Y. Quan J.D. Exec. VP, Chief Bus. Officer & Gen. Counsel
Kristina Engeseth Exec. Director and Head of People & Culture
Mr. John Fry Exec. VP of Clinical Devel.
Dr. Matthew W. McClure M.D. Exec. VP & Chief Medical Officer
Dr. Sushmita M. Chanda DABT, Ph.D. Exec. VP of Translational Safety Sciences
Dr. David B. Smith Ph.D. Exec. VP & Head of Chemical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3509
Price-to-Sales TTM: 3.7883
IPO Date: 2020-10-16
Fiscal Year End: December
Full Time Employees: 89
Back to stocks